Chikungunya vaccine
A Chikungunya vaccine is a vaccine intended to provide acquired immunity against the chikungunya virus.
| Vaccine description | |
|---|---|
| Target | Chikungunya virus |
| Vaccine type | Attenuated |
| Clinical data | |
| Trade names | Ixchiq |
| AHFS/Drugs.com | Ixchiq |
| License data | |
| Routes of administration | Intramuscular |
| ATC code |
|
| Legal status | |
| Legal status |
|
The most commonly reported side effects include headache, fatigue, muscle pain, joint pain, fever, nausea and tenderness at the injection site.
The first chikungunya vaccine was approved for medical use in the United States in November 2023.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.